Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy.

Next Previous
Trial Profile

Dual blockage with Afatinib and Trastuzumab as neooadjuvant treatment for patients with locally advanced or operable breast cancer receiving taxane-anthracycline containing chemotherapy.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Afatinib (Primary) ; Trastuzumab (Primary) ; Cyclophosphamide; Epirubicin; Paclitaxel
  • Indications Breast cancer
  • Focus Biomarker; Therapeutic Use
  • Acronyms DAFNE
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 12 Mar 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
    • 16 Jul 2013 Planned End Date changed from 1 Dec 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov.
    • 16 Jul 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top